<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">33931856</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>18</Issue><PubDate><Year>2021</Year><Month>Sep</Month></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Blocking glutamate mGlu<sub>5</sub> receptors with the negative allosteric modulator CTEP improves disease course in SOD1<sup>G93A</sup> mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>3747</StartPage><EndPage>3764</EndPage><MedlinePgn>3747-3764</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15515</ELocationID><Abstract><AbstractText Label="BACKGROUND AND PURPOSE">The pathogenesis of amyotrophic lateral sclerosis (ALS) is not fully clarified, although excessive glutamate (Glu) transmission and the downstream cytotoxic cascades are major mechanisms for motor neuron death. Two metabotropic glutamate receptors (mGlu<sub>1</sub> and mGlu<sub>5</sub> ) are overexpressed in ALS and regulate cellular disease processes. Expression and function of mGlu<sub>5</sub> receptors are altered at early symptomatic stages in the SOD1<sup>G93A</sup> mouse model of ALS and knockdown of mGlu5 receptors in SOD1<sup>G93A</sup> mice improved disease progression.</AbstractText><AbstractText Label="EXPERIMENTAL APPROACH">We treated male and female SOD1<sup>G93A</sup> mice with 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP), an orally available mGlu<sub>5</sub> receptor negative allosteric modulator (NAM), using doses of 2&#x2009;mg&#xb7;kg<sup>-1</sup> per 48&#x2009;h or 4&#x2009;mg&#xb7;kg<sup>-1</sup> per 24&#x2009;h from Day 90, an early symptomatic disease stage. Disease progression was studied by behavioural and histological approaches.</AbstractText><AbstractText Label="KEY RESULTS">CTEP dose-dependently ameliorated clinical features in SOD1<sup>G93A</sup> mice. The lower dose increased survival and improved motor skills in female mice, with barely positive effects in male mice. Higher doses significantly ameliorated disease symptoms and survival in both males and females, females being more responsive. CTEP also reduced motor neuron death, astrocyte and microglia activation, and abnormal glutamate release in the spinal cord, with equal effects in male and female mice. No differences were also observed in CTEP access to the brain.</AbstractText><AbstractText Label="CONCLUSION AND IMPLICATIONS">Our results suggest that mGlu<sub>5</sub> receptors are promising targets for the treatment of ALS and highlight mGlu5 receptor NAMs as effective pharmacological tools with translational potential.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. British Journal of Pharmacology published by John Wiley &amp; Sons Ltd on behalf of British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milanese</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inter-University Center for the Promotion of the 3Rs Principles in Teaching &amp; Research (Centro 3R), Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonifacino</LastName><ForeName>Tiziana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inter-University Center for the Promotion of the 3Rs Principles in Teaching &amp; Research (Centro 3R), Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torazza</LastName><ForeName>Carola</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Provenzano</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of T&#xfc;bingen and German Center for Neurodegenerative Diseases (DZNE), T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Mandeep</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravera</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zerbo</LastName><ForeName>Arianna Roberta</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frumento</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balbi</LastName><ForeName>Matilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>T P Nhung</ForeName><Initials>TPN</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertola</LastName><ForeName>Nadia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Experimental Medicine, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrando</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Earth, Environmental and Life Science, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viale</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Profumo</LastName><ForeName>Aldo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Ospedale policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonanno</LastName><ForeName>Giambattista</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Ospedale policlinico San Martino, Genoa, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064529">Receptor, Metabotropic Glutamate 5</NameOfSubstance></Chemical><Chemical><RegistryNumber>3KX376GY7L</RegistryNumber><NameOfSubstance UI="D018698">Glutamic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018698" MajorTopicYN="N">Glutamic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064529" MajorTopicYN="N">Receptor, Metabotropic Glutamate 5</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP)</Keyword><Keyword MajorTopicYN="N">SOD1G93A mice</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">in vivo pharmacological treatment</Keyword><Keyword MajorTopicYN="N">metabotropic glutamate receptor 5 (mGlu5 receptor)</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33931856</ArticleId><ArticleId IdType="pmc">PMC8457068</ArticleId><ArticleId IdType="doi">10.1111/bph.15515</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abd&#x2010;Elrahman, K. S., Albaker, A., de Souza, J. M., Ribeiro, F. M., Schlossmacher, M. G., Tiberi, M., Hamilton, A., &amp; Ferguson, S. S. G. (2019). A&#x3b2; oligomers induce pathophysiological mGluR5 signaling in Alzheimer's disease model mice in a sex&#x2010;selective manner. Science Signaling, 13(662), eabd2494.</Citation><ArticleIdList><ArticleId IdType="pubmed">33323410</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd&#x2010;Elrahman, K. S., Hamilton, A., Albaker, A., &amp; Ferguson, S. S. G. (2020). mGluR5 contribution to neuropathology in Alzheimer mice is disease stage&#x2010;dependent. ACS Pharmacology Translational Science, 3(2), 334&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7155195</ArticleId><ArticleId IdType="pubmed">32296772</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd&#x2010;Elrahman, K. S., Hamilton, A., Hutchinson, S. R., Liu, F., Russell, R. C., &amp; Ferguson, S. S. G. (2017). mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington's disease. Science Signaling, 10(510), pii: eaan6387. 10.1126/scisignal.aan6387</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.aan6387</ArticleId><ArticleId IdType="pubmed">29259100</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd&#x2010;Elrahman, K. S., Hamilton, A., Vasefi, M., &amp; Ferguson, S. S. G. (2018). Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models. Molecular Brain, 11(1), 19. 10.1186/s13041-018-0364-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-018-0364-9</ArticleId><ArticleId IdType="pmc">PMC5892040</ArticleId><ArticleId IdType="pubmed">29631635</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe, K., Aoki, M., Tsuji, S., Itoyama, Y., Sobue, G., Togo, M., &amp; Yoshinoet, H. (2017). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurology, 16, 505&#x2013;512. 10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A., &amp; CGTP Collaborators . (2019). The Concise Guide to PHARMACOLOGY 2019/20: G protein&#x2010;coupled receptors. British Journal of Pharmacology, 176(Suppl 1), S21&#x2013;S141. 10.1111/bph.14748</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14748</ArticleId><ArticleId IdType="pmc">PMC6844580</ArticleId><ArticleId IdType="pubmed">31710717</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., &#x2026; CGTP Collaborators . (2019). The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology, 176, S397&#x2013;S493. 10.1111/bph.14753</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14753</ArticleId><ArticleId IdType="pmc">PMC6844579</ArticleId><ArticleId IdType="pubmed">31710713</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., &#x2026; CGTP Collaborators . (2019). The Concise Guide to PHARMACOLOGY 2019/20: Ion channels. British Journal of Pharmacology, 176, S142&#x2013;S228. 10.1111/bph.14749</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14749</ArticleId><ArticleId IdType="pmc">PMC6844578</ArticleId><ArticleId IdType="pubmed">31710715</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfei, S., &amp; Baig, I. (2017). An optimized and very detailed, grams scale synthesis of CTEP, through a complete characterization of all the isolated and purified intermediates. Organic Communications, 10, 2114&#x2013;2121.</Citation></Reference><Reference><Citation>Anneser, J. M., Borasio, G. D., Berthele, A., Zieglg&#xe4;nsberger, W., &amp; T&#xf6;lle, T. R. (1999). Differential expression of group I metabotropic glutamate receptors in rat spinal cord somatic and autonomic motoneurons: Possible implications for the pathogenesis of amyotrophic lateral sclerosis. Neurobiology of Disease, 6(2), 140&#x2013;147. 10.1006/nbdi.1999.0237</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1999.0237</ArticleId><ArticleId IdType="pubmed">10343329</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica, E., Catania, M. V., Geurts, J., Yankaya, B., &amp; Troost, D. (2001). Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: Upregulation in reactive astrocytes. Neuroscience, 105, 509&#x2013;520. 10.1016/S0306-4522(01)00181-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(01)00181-6</ArticleId><ArticleId IdType="pubmed">11672616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aronica, E., van Vliet, E. A., Mayboroda, O. A., Troost, D., da Silva, F. H., &amp; Gorter, J. A. (2000). Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. The European Journal of Neuroscience, 12, 2333&#x2013;2344. 10.1046/j.1460-9568.2000.00131.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.2000.00131.x</ArticleId><ArticleId IdType="pubmed">10947812</ArticleId></ArticleIdList></Reference><Reference><Citation>Arsova, A., M&#xf8;ller, T. C., Vedel, L., Hansen, J. L., Foster, S. R., Gregory, K. J., &amp; Br&#xe4;uner&#x2010;Osborne, H. (2020). Detailed in vitro pharmacological characterization of clinically tested negative allosteric modulators of the metabotropic glutamate receptor 5 (mGlu5). Molecular Pharmacology, 98(1), 49&#x2013;60. 10.1124/mol.119.119032</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/mol.119.119032</ArticleId><ArticleId IdType="pmc">PMC7705108</ArticleId><ArticleId IdType="pubmed">32358164</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonanno, G., &amp; Raiteri, M. (1987). Coexistence of carriers for dopamine and GABA uptake on a same nerve terminal in the rat brain. British Journal of Pharmacology, 91(1), 237&#x2013;243. 10.1111/j.1476-5381.1987.tb09004.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1476-5381.1987.tb09004.x</ArticleId><ArticleId IdType="pmc">PMC1853497</ArticleId><ArticleId IdType="pubmed">3594080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino, T., Cattaneo, L., Gallia, E., Puliti, A., Melone, M., Provenzano, F., Bossi, S., Musante, I., Usai, C., Conti, F., Bonanno, G., &amp; Milanese, M. (2017). In&#x2010;vivo effects of knocking&#x2010;down metabotropic glutamate receptor 5 in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuropharmacology, 123, 433&#x2013;445. 10.1016/j.neuropharm.2017.06.020</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2017.06.020</ArticleId><ArticleId IdType="pubmed">28645622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino, T., Musazzi, L., Milanese, M., Seguini, M., Marte, A., Gallia, E., Cattaneo, L., Onofri, F., Popoli, M., &amp; Bonanno, G. (2016). Altered mechanisms underlying the abnormal glutamate release in amyotrophic lateral sclerosis at a presymptomatic stage of the disease. Neurobiology of Disease, 95, 122&#x2013;133. 10.1016/j.nbd.2016.07.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2016.07.011</ArticleId><ArticleId IdType="pubmed">27425885</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino, T., Provenzano, F., Gallia, E., Ravera, S., Torazza, C., Bossi, S., Ferrando, S., Puliti, A., Van Den Bosch, L., Bonanno, G., &amp; Milanese, M. (2019). In&#x2010;vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 129, 79&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">31102766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacino, T., Rebosio, C., Provenzano, F., Torazza, C., Balbi, M., Milanese, M., Raiteri, L., Usai, C., Fedele, E., &amp; Bonanno, G. (2019). Enhanced function and overexpression of metabotropic glutamate receptors 1 and 5 in the spinal cord of the SOD1G93A mouse model of amyotrophic lateral sclerosis during disease progression. International Journal of Molecular Sciences, 20(18), 4552. 10.3390/ijms20184552</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20184552</ArticleId><ArticleId IdType="pmc">PMC6774337</ArticleId><ArticleId IdType="pubmed">31540330</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownell, A. L., Kuruppu, D., Kil, K. E., Jokivarsi, K., Poutiainen, P., Zhu, A., &amp; Maxwell, M. (2015). PET imaging studies show enhanced expression of mGluR5 and inflammatory response during progressive degeneration in ALS mouse model expressing SOD1&#x2010;G93A gene. Journal of Neuroinflammation, 12, 217. 10.1186/s12974-015-0439-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0439-9</ArticleId><ArticleId IdType="pmc">PMC4657381</ArticleId><ArticleId IdType="pubmed">26597638</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2;, A., Battistini, S., Calvo, A., Caponnetto, C., Conforti, F. L., Corbo, M., Giannini, F., Mandrioli, J., Mora, G., Sabatelli, M., TALSGEN Consortium , Ajmone, C., Mastro, E., Pain, D., Mandich, P., Pendo, S., Restagno, G., Zollino, M., &amp; Surbone, A. (2014). Genetic counselling in ALS: Facts, uncertainties and clinical suggestions. Journal of Neurology, Neurosurgery, and Psychiatry, 85(5), 478&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis, M. J., Bond, R. A., Spina, D., Ahluwalia, A., Alexander, S. P., Giembycz, M. A., Gilchrist, A., Hoyer, D., Insel, P. A., Izzo, A. A., Lawrence, A. J., MacEwan, D. J., Moon, L. D., Wonnacott, S., Weston, A. H., &amp; McGrath, J. C. (2015). Experimental design and analysis and their reporting: New guidance for publication in BJP. British Journal of Pharmacology, 172(14), 3461&#x2013;3471. 10.1111/bph.12856</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.12856</ArticleId><ArticleId IdType="pmc">PMC4507152</ArticleId><ArticleId IdType="pubmed">26114403</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Antoni, S., Berretta, A., Seminara, G., Longone, P., Giuffrida&#x2010;Stella, A. M., Battaglia, G., Sortino, M. A., Nicoletti, F., &amp; Catania, M. V. (2011). A prolonged pharmacological blockade of type&#x2010;5 metabotropic glutamate receptors protects cultured spinal cord motor neurons against excitotoxic death. Neurobiology of Disease, 42(3), 252&#x2013;264. 10.1016/j.nbd.2011.01.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2011.01.013</ArticleId><ArticleId IdType="pubmed">21232601</ArticleId></ArticleIdList></Reference><Reference><Citation>D'Antoni, S., Berretta, A., Bonaccorso, C. M., Bruno, V., Aronica, E., Nicoletti, F., &amp; Catania, M. V. (2008). Metabotropic glutamate receptors in glial cells. Neurochemical Research, 33(12), 2436&#x2013;2443. 10.1007/s11064-008-9694-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-008-9694-9</ArticleId><ArticleId IdType="pubmed">18438710</ArticleId></ArticleIdList></Reference><Reference><Citation>Doble, A. (1996). The pharmacology and mechanism of action of riluzole. Neurology, 47(Issue 6, Supplement 4), 233S&#x2013;241S. 10.1212/wnl.47.6_suppl_4.233s</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.47.6_suppl_4.233s</ArticleId><ArticleId IdType="pubmed">8959995</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst, J., Ludolph, A. C., &amp; Huebers, A. (2017). Disease&#x2010;modifying and symptomatic treatment of amyotrophic lateral sclerosis. Therapeutic Advances in Neurological Disorders. 11, 175628561773473. 10.1177/1756285617734734</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756285617734734</ArticleId><ArticleId IdType="pmc">PMC5784546</ArticleId><ArticleId IdType="pubmed">29399045</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouin&#x2010;Ouellet, J., Brownell, A. L., Saint&#x2010;Pierre, M., Fasano, C., Emond, V., Trudeau, L. E., L&#xe9;vesque, D., &amp; Cicchetti, F. (2011). Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions. Glia, 59(2), 188&#x2013;199. 10.1002/glia.21086</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.21086</ArticleId><ArticleId IdType="pmc">PMC3983848</ArticleId><ArticleId IdType="pubmed">21125661</ArticleId></ArticleIdList></Reference><Reference><Citation>Dukkipati, S. S., Garrett, T. L., &amp; Elbasiouny, S. M. (2018). The vulnerability of spinal motoneurons and soma size plasticity in a mouse model of amyotrophic lateral sclerosis. The Journal of Physiology, 596(9), 1723&#x2013;1745. 10.1113/JP275498</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/JP275498</ArticleId><ArticleId IdType="pmc">PMC5924829</ArticleId><ArticleId IdType="pubmed">29502344</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisen, A. (2009). Amyotrophic lateral sclerosis: A 40&#x2010;year personal perspective. Journal of Clinical Neuroscience, 16, 505&#x2013;512. 10.1016/j.jocn.2008.07.072</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2008.07.072</ArticleId><ArticleId IdType="pubmed">19231200</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer, K., Abd&#x2010;Elrahman, K. S., Derksen, A., Rowe, E. M., Thompson, A. M., Rudyk, C. A., Prowse, N. A., Dwyer, Z., Bureau, S., Fortin, T., Ferguson, S. G., &amp; Hayley, S. (2020). mGluR5 allosteric modulation promotes neurorecovery in a 6&#x2010;OHDA&#x2010;toxicant model of Parkinson's disease. Molecular Neurobiology, 57(3), 1418&#x2013;1431. 10.1007/s12035-019-01818-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-01818-z</ArticleId><ArticleId IdType="pubmed">31754998</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo, L., Kirby, J., Grierson, A. J., Sendtner, M., &amp; Shaw, P. J. (2011). Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nature Reviews Neurology, 7(11), 616&#x2013;630. 10.1038/nrneurol.2011.152</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>Filipi, T., Hermanova, Z., Tureckova, J., Vanatko, O., &amp; Anderova, M. (2020). Glial cells&#x2014;The strategic targets in amyotrophic lateral sclerosis treatment. Journal of Clinical Medicine, 9(1), 261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7020059</ArticleId><ArticleId IdType="pubmed">31963681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleck, M. W., Barrionuevo, G., &amp; Palmer, A. M. (2001). Synaptosomal and vesicular accumulation of l&#x2010;glutamate, l&#x2010;aspartate and d&#x2010;aspartate. Neurochemistry International, 39, 217&#x2013;225. 10.1016/S0197-0186(01)00018-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-0186(01)00018-3</ArticleId><ArticleId IdType="pubmed">11434980</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes, A. E., Braun, L., Ferraiuolo, L., Guttridge, D. C., &amp; Kaspar, B. K. (2017). Additive amelioration of ALS by co&#x2010;targeting independent pathogenic mechanisms. Annals of Clinical Translational Neurology, 4(2), 76&#x2013;86. 10.1002/acn3.375</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.375</ArticleId><ArticleId IdType="pmc">PMC5288461</ArticleId><ArticleId IdType="pubmed">28168207</ArticleId></ArticleIdList></Reference><Reference><Citation>Giribaldi, F., Milanese, M., Bonifacino, T., Rossi, P. I. A., Di Prisco, S., Pittaluga, A., Tacchetti, C., Puliti, A., Usai, C., &amp; Bonanno, G. (2013). Group I metabotropic glutamate autoreceptors induce abnormal glutamate exocytosis in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology, 66, 253&#x2013;263. 10.1016/j.neuropharm.2012.05.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2012.05.018</ArticleId><ArticleId IdType="pubmed">22634363</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, D. D., Caliendo, J., Hentati, A., Kwon, Y. W., Deng, H. X., &amp; Siddique, T. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 264(5166), 1772&#x2013;1775. 10.1126/science.8209258</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbet, T., Drapeau, P., Pradier, L., &amp; Dunn, R. J. (1994). Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol., 45(5), 1055&#x2013;1060. https://pubmed.ncbi.nlm.nih.gov/8190096/
</Citation><ArticleIdList><ArticleId IdType="pubmed">8190096</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter&#x2010;Stoll, N., Boissin, P., Borroni, E., B&#xfc;ttelmann, B., Ceccarelli, S., Clemann, N., David, B., Funk, C., Guba, W., Harrison, A., Hartung, T., Honer, M., Huwyler, J., Kuratli, M., Niederhauser, U., &#x2026; Lindemann, L. (2015). Metabotropic glutamate receptor 5 negative allosteric modulators: Discovery of 2&#x2010;chloro&#x2010;4&#x2010;[1&#x2010;(4&#x2010;fluorophenyl)&#x2010;2,5&#x2010;dimethyl&#x2010;1H&#x2010;imidazol&#x2010;4&#x2010;ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. Journal of Medicinal Chemistry, 58(3), 1358&#x2013;1371. 10.1021/jm501642c</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm501642c</ArticleId><ArticleId IdType="pubmed">25565255</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, R. B., Irvin, C. W., Tilva, K. R., &amp; Mitchell, C. S. (2015). State of the field: An informatics&#x2010;based systematic review of the SOD1&#x2010;G93A amyotrophic lateral sclerosis transgenic mouse model. Amyotroph Lateral Scler Frontotemporal Degener., 17(1&#x2013;2), 1&#x2013;14. 10.3109/21678421.2015.1047455</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1047455</ArticleId><ArticleId IdType="pmc">PMC4724331</ArticleId><ArticleId IdType="pubmed">25998063</ArticleId></ArticleIdList></Reference><Reference><Citation>King, A. E., Woodhouse, A., Kirkcaldie, Ma. T. K., &amp; Vickers, J. C. (2016). Excitotoxicity in ALS: Overstimulation, or overreaction? Experimental Neurology, 275, 162&#x2013;171. 10.1016/j.expneurol.2015.09.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.09.019</ArticleId><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Klivenyi, P., Kiaei, M., Gardian, G., Calingasan, N. Y., &amp; Beal, M. F. (2004). Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 88(3), 576&#x2013;582. 10.1046/j.1471-4159.2003.02160.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.02160.x</ArticleId><ArticleId IdType="pubmed">14720207</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriz, J., Gowing, G., &amp; Julien, J. P. (2003). Efficient three&#x2010;drug cocktail for disease induced by mutant superoxide dismutase. Annals of Neurology, 53(4), 429&#x2013;436. 10.1002/ana.10500</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10500</ArticleId><ArticleId IdType="pubmed">12666110</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Gall, L., Anakor, E., Connolly, O., Vijayakumar, U. G., Duddy, W. J., &amp; Duguez, S. (2020). Molecular and cellular mechanisms affected in ALS. Journal of Personalized Medicine, 10(3), 101. 10.3390/jpm10030101</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm10030101</ArticleId><ArticleId IdType="pmc">PMC7564998</ArticleId><ArticleId IdType="pubmed">32854276</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, Z., Ji, G., &amp; Neugebauer, V. (2011). Mitochondrial reactive oxygen species are activated by mGluR5 through IP3 and activate ERK and PKA to increase excitability of amygdala neurons and pain behavior. The Journal of Neuroscience, 31(3), 1114&#x2013;1127. 10.1523/JNEUROSCI.5387-10.2011</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5387-10.2011</ArticleId><ArticleId IdType="pmc">PMC3073477</ArticleId><ArticleId IdType="pubmed">21248136</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., &amp; Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology. 177(16), 3611&#x2013;3616. 10.1111/bph.15178</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15178</ArticleId><ArticleId IdType="pmc">PMC7393193</ArticleId><ArticleId IdType="pubmed">32662875</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindemann, L., GJaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., THartung, T., Kolczewski, S., Buttelmann, B., Flament, C., Diener, C., Fischer, C., Gatti, S., Prinssen, E., Parrott, N., Hoffmann, G., &amp; Wettstein, J. (2011). CTEP: A novel, potent, long&#x2010;acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 339(2), 474&#x2013;486. 10.1124/jpet.111.185660</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.111.185660</ArticleId><ArticleId IdType="pubmed">21849627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., Schneider, M., Parrott, N. J., Polonchuk, L., Niederhauser, U., Morairty, S. R., Kilduff, T. S., Vieira, E., Kolczewski, S., Wichmann, J., &#x2026; Jaeschke, G. (2015). Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. The Journal of Pharmacology and Experimental Therapeutics, 353(1), 213&#x2013;233. 10.1124/jpet.114.222463</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.114.222463</ArticleId><ArticleId IdType="pubmed">25665805</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, F., Zhou, R., Yan, H., Yin, H., Wu, X., Tan, Y., &amp; Li, L. (2014). Metabotropic glutamate receptor 5 modulates calcium oscillation and innate immune response induced by lipopolysaccharide in microglial cell. Neuroscience, 281, 24&#x2013;34. 10.1016/j.neuroscience.2014.09.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2014.09.034</ArticleId><ArticleId IdType="pubmed">25250840</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, H., Le, W. D., Xie, Y.&#x2010;Y., &amp; Wang, X.&#x2010;P. (2016). Current therapy of drugs in amyotrophic lateral sclerosis. Current Neuropharmacology, 14, 314&#x2013;321. 10.2174/1570159X14666160120152423</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X14666160120152423</ArticleId><ArticleId IdType="pmc">PMC4876587</ArticleId><ArticleId IdType="pubmed">26786249</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph, A. C., Bendotti, C., Blaugrund, E., Hengerer, B., L&#xf6;ffler, J. P., Martin, J., Meininger, V., Meyer, T., Moussaoui, S., Robberecht, W., Scott, S., Silani, V., Van Den Berg, L. H., &amp; ENMC Group for the Establishment of Guidelines for the Conduct of Preclinical and Proof of Concept Studies in ALS/MND Models . (2007). Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop. Amyotrophic Lateral Sclerosis, 8(4), 217&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pubmed">17653919</ArticleId></ArticleIdList></Reference><Reference><Citation>Luong, T. N., Carlisle, H. J., Southwell, A., &amp; Patterson, P. H. (2011). Assessment of Motor Balance and Coordination in Mice using the Balance Beam. Journal of Visualized Experiments, (49). 10.3791/2376</Citation><ArticleIdList><ArticleId IdType="doi">10.3791/2376</ArticleId><ArticleId IdType="pmc">PMC3197288</ArticleId><ArticleId IdType="pubmed">21445033</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese, M., Bonifacino, T., Fedele, E., Rebosio, C., Cattaneo, L., Benfenati, F., Usai, C., &amp; Bonanno, G. (2015). Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: A mechanism for the excessive heterotransporter&#x2010;induced release of glutamate in experimental amyotrophic lateral sclerosis. Neurobiology of Disease, 74, 314&#x2013;324. 10.1016/j.nbd.2014.12.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.12.004</ArticleId><ArticleId IdType="pubmed">25497732</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese, M., Giribaldi, F., Melone, M., Bonifacino, T., Musante, I., Carminati, E., Rossi, P. I. A., Vergani, A., Conti, F., Puliti, A., &amp; Bonanno, G. (2014). Knocking down metabotropic glutamate receptor 1 improves survival and disease progression in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease, 64, 48&#x2013;59. 10.1016/j.nbd.2013.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2013.11.006</ArticleId><ArticleId IdType="pubmed">24361555</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese, M., Zappettini, S., Jacchetti, E., Bonifacino, T., Cervetto, C., Usai, C., &amp; Bonanno, G. (2010). In vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse model of amyotrophioc lateral sclerosis. Journal of Neurochemistry, 113, 489&#x2013;501. 10.1111/j.1471-4159.2010.06628.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06628.x</ArticleId><ArticleId IdType="pubmed">20132478</ArticleId></ArticleIdList></Reference><Reference><Citation>Milanese, M., Zappettini, S., Onofri, F., Musazzi, L., Tardito, D., Bonifacino, T., Messa, M., Racgni, G., Usai, C., Benfenati, F., Popoli, M., &amp; Bonanno, G. (2011). Abnormal exocytotic release of glutamate in a mouse model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 116, 1028&#x2013;1042. 10.1111/j.1471-4159.2010.07155.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07155.x</ArticleId><ArticleId IdType="pubmed">21175617</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J., &amp; Pin, J. P. (2011). Metabotropic glutamate receptors: From the workbench to the bedside. Neuropharmacology, 60(7&#x2013;8), 1017&#x2013;1041. 10.1016/j.neuropharm.2010.10.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2010.10.022</ArticleId><ArticleId IdType="pmc">PMC3787883</ArticleId><ArticleId IdType="pubmed">21036182</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco, R., Ciruela, F., Casad&#xf3;, V., Mallol, J., Gallart, T., Lluis, C., &amp; Franco, R. J. (2004). Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. Biological Chemistry, 279(32), 33352&#x2013;33358. 10.1074/jbc.M401761200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M401761200</ArticleId><ArticleId IdType="pubmed">15184389</ArticleId></ArticleIdList></Reference><Reference><Citation>Panatier, A., &amp; Robitaille, R. (2016). Astrocytic mGluR5 and the tripartite synapse. Neuroscience, 323, 29&#x2013;34. 10.1016/j.neuroscience.2015.03.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.03.063</ArticleId><ArticleId IdType="pubmed">25847307</ArticleId></ArticleIdList></Reference><Reference><Citation>Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., &#x2026; W&#xfc;rbel, H. (2020). The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. British Journal of Pharmacology, 4(1), e100115. 10.1136/bmjos-2020-100115</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjos-2020-100115</ArticleId><ArticleId IdType="pmc">PMC7610906</ArticleId><ArticleId IdType="pubmed">34095516</ArticleId></ArticleIdList></Reference><Reference><Citation>Quiroz, J. A., Tamburri, P., Deptula, D., Banken, L., Beyer, U., Rabbia, M., Parkar, N., Fontoura, P., &amp; Santarelli, L. (2016). Efficacy and safety of basimglurant as adjunctive therapy for major depression: A randomized clinical trial. JAMA Psychiatry, 73(7), 675&#x2013;684. 10.1001/jamapsychiatry.2016.0838</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2016.0838</ArticleId><ArticleId IdType="pubmed">27304433</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri, L., Zappettini, S., Milanese, M., Fedele, E., Raiteri, M., &amp; Bonanno, G. (2007). Mechanisms of glutamate release elicited in rat cerebrocortical nerve endings by &#x2018;pathologically&#x2019; elevated extraterminal K+concentrations. Journal of Neurochemistry, 103(3), 952&#x2013;961. 10.1111/j.1471-4159.2007.04784.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04784.x</ArticleId><ArticleId IdType="pubmed">17662048</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiteri, L., Stigliani, S., Zappettini, S., Mercuri, N. B., Raiteri, M., &amp; Bonanno, G. (2004). Excessive and precocious glutamate release in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology, 46(6), 782&#x2013;792. 10.1016/j.neuropharm.2003.11.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2003.11.025</ArticleId><ArticleId IdType="pubmed">15033338</ArticleId></ArticleIdList></Reference><Reference><Citation>Reilmann, R., Rouzade&#x2010;Dominguez, M. L., Saft, C., S&#xfc;ssmuth, S. D., Priller, J., Rosser, A., Rickards, H., Sch&#xf6;ls, L., Pezous, N., Gasparini, F., Johns, D., Landwehrmeyer, G. B., &amp; Gomez&#x2010;Mancilla, B. (2015). A randomized, placebo&#x2010;controlled trial of AFQ056 for the treatment of chorea in Huntington's disease. Movement Disorders, 30(3), 427&#x2013;431. 10.1002/mds.26174</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26174</ArticleId><ArticleId IdType="pubmed">25689146</ArticleId></ArticleIdList></Reference><Reference><Citation>Ribeiro, F. M., Vieira, L. B., Pires, R. G., Olmo, R. P., &amp; Ferguson, S. S. (2017). Metabotropic glutamate receptors and neurodegenerative diseases. Pharmacological Research, 115, 179&#x2013;191. 10.1016/j.phrs.2016.11.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.11.013</ArticleId><ArticleId IdType="pubmed">27872019</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi, D., Brambilla, L., Valori, C. F., Roncoroni, C., Crugnola, A., Yokota, T., Bredesen, D. E., &amp; Volterra, A. (2008). Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differentiation, 15, 1691&#x2013;1700. 10.1038/cdd.2008.99</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2008.99</ArticleId><ArticleId IdType="pubmed">18617894</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein, J. D., Martin, L. J., &amp; Kuncl, R. W. (1992). Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. The New England Journal of Medicine, 326, 1464&#x2013;1468. 10.1056/NEJM199205283262204</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199205283262204</ArticleId><ArticleId IdType="pubmed">1349424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J., &amp; Kuncl, R. W. (1995). Selective loss of glial glutamate transporter GLT&#x2010;1 in amyotrophic lateral sclerosis. Annals of Neurology, 38(1), 73&#x2013;84. 10.1002/ana.410380114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410380114</ArticleId><ArticleId IdType="pubmed">7611729</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah, A., Silverstein, P. S., Singh, D. P., &amp; Kumar, A. (2012). Involvement of metabotropic glutamate receptor 5, AKT/PI3K signaling and NF&#x2010;&#x3ba;B pathway in methamphetamine&#x2010;mediated increase in IL&#x2010;6 and IL&#x2010;8 expression in astrocytes. Journal of Neuroinflammation, 9, 52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3338363</ArticleId><ArticleId IdType="pubmed">22420994</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw, P. J., Forrest, V., Ince, P. G., Richardson, J. P., &amp; Wastell, H. J. (1995). CSF and plasma amino acid levels in motorneuron disease: Elevation of CSF glutamate in a subset of patients. Neurodegeneration, 4(2), 209&#x2013;216. 10.1006/neur.1995.0026</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/neur.1995.0026</ArticleId><ArticleId IdType="pubmed">7583686</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon, J. A., Tarnopolsky, M. A., &amp; Hamadeh, M. J. (2011). One universal common endpoint in mouse models of amyotrophic lateral sclerosis. PLoS ONE, 6(6), e20582. 10.1371/journal.pone.0020582</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0020582</ArticleId><ArticleId IdType="pmc">PMC3110799</ArticleId><ArticleId IdType="pubmed">21687686</ArticleId></ArticleIdList></Reference><Reference><Citation>Trenkwalder, C., Stocchi, F., Poewe, W., Dronamraju, N., Kenney, C., Shah, A., von Raison, F., &amp; Graf, A. (2016). Mavoglurant in Parkinson's patients with l&#x2010;Dopa&#x2010;induced dyskinesias: Two randomized phase 2 studies. Movement Disorders, 31(7), 1054&#x2013;1058. 10.1002/mds.26585</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26585</ArticleId><ArticleId IdType="pubmed">27214258</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner, P. V., Brabb, T., Pekow, C., &amp; Vasbinder, M. A. (2011). Administration of substances to laboratory animals: Routes of administration and factors to consider. Journal of the American Association for Laboratory Animal Science, 50(5), 600&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3189662</ArticleId><ArticleId IdType="pubmed">22330705</ArticleId></ArticleIdList></Reference><Reference><Citation>Uccelli, A., Milanese, M., Principato, M. C., Morando, S., Bonifacino, T., Vergani, L., Giunti, D., Voci, A., Carminati, E., Giribaldi, F., Caponetto, C., &amp; Bonanno, G. (2012). Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis. Molecular Medicine, 18, 794&#x2013;804. 10.2119/molmed.2011.00498</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2011.00498</ArticleId><ArticleId IdType="pmc">PMC3409288</ArticleId><ArticleId IdType="pubmed">22481270</ArticleId></ArticleIdList></Reference><Reference><Citation>Valerio, A., Ferrario, M., Paterlini, M., Liberini, P., Moretto, G., Cairns, N. J., Pizzi, M., &amp; Spano, P. (2002). Spinal cord mGlu1a receptors: Possible target for amyotrophic lateral sclerosis therapy. Pharmacology, Biochemistry, and Behavior, 73(2), 447&#x2013;454. 10.1016/S0091-3057(02)00835-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0091-3057(02)00835-3</ArticleId><ArticleId IdType="pubmed">12117600</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch, L., Van Damme, P., Bogaert, E., &amp; Robberecht, W. (2006). The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochimica et Biophysica Acta, 1762(11&#x2013;12), 1068&#x2013;1082. 10.1016/j.bbadis.2006.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2006.05.002</ArticleId><ArticleId IdType="pubmed">16806844</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber, N. K., Shepheard, S. R., Sassani, M., McDonough, H. E., Moore, S. A., Alix, J. J. P., Wilkinson, I. D., Jenkins, T. M., &amp; Shaw, P. J. (2019). Biomarkers in motor neuron disease: A state of the art review. Frontiers in Neurology, 10, 291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergouts, M., Doyen, P. J., Peeters, M., Opsomer, R., &amp; Hermans, E. (2018). Constitutive downregulation protein kinase C epsilon in hSOD1G93A astrocytes influences mGluR5 signaling and the regulation of glutamate uptake. Glia, 66, 749&#x2013;761. 10.1002/glia.23279</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23279</ArticleId><ArticleId IdType="pubmed">29266405</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeiren, C., Hemptinne, I., Vanhoutte, N., Tilleux, S., Maloteaux, J. M., &amp; Hermans, E. (2006). Loss of metabotropic glutamate receptor&#x2010;mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis. Journal of Neurochemistry, 96(3), 719&#x2013;731. 10.1111/j.1471-4159.2005.03577.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03577.x</ArticleId><ArticleId IdType="pubmed">16371010</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeiren, C., Najimi, M., Vanhoutte, N., Tilleux, S., de Hemptinne, I., Maloteaux, J. M., &amp; Hermans, E. (2005). Acute up&#x2010;regulation of glutamate uptake mediated by mGluR5a in reactive astrocytes. Journal of Neurochemistry, 94(2), 405&#x2013;416. 10.1111/j.1471-4159.2005.03216.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03216.x</ArticleId><ArticleId IdType="pubmed">15998291</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant, S., Mansfield, C., Jimenez&#x2010;Moreno, R., Del Gaizo Moore, V., Yoshikawa, M., Hampton, T. G., Prevette, D., Caress, J., Oppenheim, R. W., &amp; Milligan, C. (2013). Characterization of early pathogenesis in the SOD1G93A mouse model of ALS: Part II, results and discussion. Brain and Behavior: A Cognitive Neuroscience Perspective, 3(4), 431&#x2013;457. 10.1002/brb3.142</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/brb3.142</ArticleId><ArticleId IdType="pmc">PMC3869683</ArticleId><ArticleId IdType="pubmed">24381813</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L., &amp; Nadler, J. V. (2007). Reduced aspartate release from rat hippocampal synaptosomes loaded with Clostridial toxin light chain by electroporation: Evidence for an exocytotic mechanism. Neuroscience Letters, 412(3), 239&#x2013;242. 10.1016/j.neulet.2006.11.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.11.006</ArticleId><ArticleId IdType="pmc">PMC1809225</ArticleId><ArticleId IdType="pubmed">17123709</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson, C., Paxinos, G., Kayalioglu, G., &amp; Heise, C. (2009). Chapter 15 &#x2010; Atlas of the Rat Spinal Cord &amp; The Spinal Cord: A Christopher and Dana Reeve Foundation Text and Atlas. (238&#x2013;306). Academic Press. https://www.sciencedirect.com/science/article/pii/B9780123742476500195
</Citation></Reference><Reference><Citation>Youssef, E. A., Berry&#x2010;Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., Kinch, R., Drewitt, P., Lindemann, L., Marcinowski, M., Langland, R., Horn, C., Fontoura, P., Santarelli, L., Quiroz, J. A., &amp; FragXis Study Group . (2018). Effect of the mGluR5&#x2010;NAM basimglurant on behavior in adolescents and adults with fragile X syndrome in a randomized, double&#x2010;blind, placebo&#x2010;controlled trial: FragXis Phase 2 results. Neuropsychopharmacology, 43(3), 503&#x2013;512. 10.1038/npp.2017.177</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2017.177</ArticleId><ArticleId IdType="pmc">PMC5770759</ArticleId><ArticleId IdType="pubmed">28816242</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, W., Narayanan, M., &amp; Friedlander, R. M. (2003). Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Annals of Neurology, 53(2), 267&#x2013;270. 10.1002/ana.10476</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10476</ArticleId><ArticleId IdType="pubmed">12557297</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>